---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-08-18T09:23:11.975305'
end_time: '2026-08-18T09:33:55.585435'
duration_seconds: 643.61
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Noonan Syndrome 11
  mondo_id: ''
  category: Genetic
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    max_embedded_images: 8
citation_count: 19
reference_validation:
  total_references: 6
  verified: 6
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 6
  on_topic: 5
  validator_version: 0.2.1
artifact_count: 1
artifact_sources:
  edison_answer_artifacts: 1
artifacts:
- filename: artifact-00.md
  path: Noonan_Syndrome_11-deep-research-falcon_artifacts/artifact-00.md
  media_type: text/markdown
  source: edison_answer_artifacts
  data_storage_id: null
  description: Edison artifact artifact-00
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Noonan Syndrome 11
- **MONDO ID:**  (if available)
- **Category:** Genetic

## Research Objectives

Please provide a comprehensive research report on **Noonan Syndrome 11** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Noonan Syndrome 11
- **MONDO ID:**  (if available)
- **Category:** Genetic

## Research Objectives

Please provide a comprehensive research report on **Noonan Syndrome 11** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


# Noonan Syndrome 11: comprehensive disease-characteristics report

## Scope and nomenclature warning

The requested name **“Noonan syndrome 11” is not the designation used for dominant LZTR1-related Noonan syndrome in the retrieved authoritative literature**. The relevant disorder is generally called **autosomal-dominant LZTR1-related Noonan syndrome** or **Noonan syndrome 10 (NS10), OMIM #616564**. It must be distinguished from autosomal-recessive LZTR1-related Noonan syndrome—called NS2, OMIM #605275 in the retrieved review—and from LZTR1-related schwannomatosis. Accordingly, this report treats the target disease as **dominant LZTR1-related Noonan syndrome**, while preserving “Noonan syndrome 11” as a user-supplied, unverified synonym. The broader MONDO entry is **MONDO:0018997, Noonan syndrome**; a separate MONDO identifier for this LZTR1 subtype was not established by the retrieved evidence. Open Targets reports a strong LZTR1–Noonan syndrome association (score 0.872) supported by five evidence records, including ClinGen RASopathy Expert Panel evidence and PMIDs 25795793, 29469822, 30481304, 30859559, 30664951, and others. (uliana2024phenotypicexpansionof pages 14-16, uliana2024phenotypicexpansionof pages 1-2, OpenTargets Search: Noonan syndrome-LZTR1)

| Domain | Best-supported finding | Quantitative data | Evidence type/source/date | Knowledge-base implication |
|---|---|---|---|---|
| Disease identity / nomenclature | The user’s label “Noonan syndrome 11” does not match the dominant **LZTR1** literature most directly retrieved here; published sources describe **autosomal-dominant LZTR1-related Noonan syndrome** as **OMIM 616564 / Noonan syndrome 10**. Broad disease mapping evidence is available for **Noonan syndrome (MONDO:0018997)**, but a subtype-specific MONDO/OMIM identifier for “NS11” was not confirmed from retrieved sources. | OMIM 616564 cited in 2024 review; Open Targets shows LZTR1–Noonan syndrome association evidence count 5 | Review and disease-target curation, 2024; Open Targets evidence (uliana2024phenotypicexpansionof pages 14-16, uliana2024phenotypicexpansionof pages 1-2, OpenTargets Search: Noonan syndrome-LZTR1) | Store as **autosomal-dominant LZTR1-related Noonan syndrome** with a nomenclature caveat note; avoid asserting an unverified NS11 subtype identifier. |
| Core phenotype | Dominant LZTR1-related Noonan syndrome has a broadly classic Noonan phenotype with multisystem involvement, but current best frequency estimates come from a small literature-derived cohort. | 51 patients; short stature 68.3%, cardiac defects 66%, skeletal abnormalities 58%, global developmental delay 32%, abnormal hemostasis 27%; median age 17.2 years (range 2–69) | Human literature synthesis/review, Genes, Jul 2024 (uliana2024phenotypicexpansionof pages 4-5) | Add phenotype-frequency assertions with evidence level “compiled published cases, small cohort.” |
| Variant spectrum | Dominant disease is enriched for **missense** variants affecting the **Kelch domain**, unlike schwannomatosis where loss-of-function variants are more common. **p.Gly248Arg** is a recurrent hotspot. | 77% missense; 87% Kelch-domain; p.Gly248Arg reported in 6 families | Human review/synthesis, Jul 2024 (uliana2024phenotypicexpansionof pages 16-17) | Prioritize Kelch-domain missense variants in curation and variant interpretation rules for dominant disease. |
| Inheritance | LZTR1 can cause both dominant and recessive Noonan syndrome; the dominant form is usually heterozygous, often de novo, and shows variable expressivity/incomplete penetrance. | DDD study: 6 dominantly acting mutations among 9,624 exomes; 5/6 de novo; LZTR1 explained ~0.1% of the full DDD cohort | Human clinical genetics, Clinical Genetics, Apr 2019 (pagnamenta2019delineationofdominant pages 1-2, uliana2024phenotypicexpansionof pages 14-16) | Distinguish **AD LZTR1-NS** from **AR LZTR1-NS** and from **schwannomatosis** in the knowledge model. |
| Foundational causal evidence | LZTR1 was established as a Noonan gene by rare-variant discovery and later phenotype-focused delineation. | Initial association reported 2015; later dominant and recessive forms delineated 2019 | Human gene discovery and follow-up genetics (pagnamenta2019delineationofdominant pages 1-2) | Mark gene-disease validity as strongly supported by multiple independent human studies. |
| Molecular mechanism | Dominant Noonan-causing LZTR1 variants act mainly through a **dominant-negative** mechanism affecting the **CUL3-LZTR1 ubiquitin ligase substrate-recognition surface**, impairing RAS-family proteostasis and increasing RAS/MAPK signaling. | Dominant variants cluster around Kelch/KT1-4 substrate-recognition regions; mechanistic studies show increased RAS protein pool and enhanced stimulus-dependent RAS-MAPK signaling | Functional human/in vitro/computational studies, 2019; review update 2024 (motta2019dominantnoonansyndromecausing pages 1-2, motta2019dominantnoonansyndromecausing pages 1-1, uliana2024phenotypicexpansionof pages 14-16) | Annotate mechanism as **dominant-negative dysregulation of RAS proteostasis** rather than simple haploinsufficiency. |
| Animal / multi-omics model | 2024 knock-in mice carrying dominant Lztr1 variants reproduced Noonan-like features and showed cardiac MAPK activation; **trametinib** improved hypertrophy. | Two KI models: **Lztr1G245R/+** and **Lztr1R409C/+**; male mice showed low birth weight, facial features, cardiac hypertrophy; reduced survival in R409C/+ mice (~25% at 2 years reported in extracted evidence) | In vivo mouse + RNA-seq/proteomics, JCI Insight, Nov 2024 (abe2024dysregulationofras pages 8-11, abe2024dysregulationofras pages 1-2, abe2024dysregulationofras pages 2-4) | Strong preclinical support for MAPK-directed therapy concepts; model is suitable for mechanistic and therapeutic annotation. |
| Therapeutic signal | MEK-pathway inhibition is the clearest mechanistically aligned intervention signal for dominant LZTR1 disease, but evidence remains preclinical/subtype-extrapolated. | Trametinib ameliorated cardiac hypertrophy in dominant LZTR1 mouse models; no LZTR1-specific human interventional trial identified in retrieved records | Mouse experiment 2024; broader NS therapeutic reviews/trials are mostly non-LZTR1-specific (abe2024dysregulationofras pages 8-11, abe2024dysregulationofras pages 1-2) | Encode trametinib/MEK inhibition as **experimental / preclinical rationale**, not established care for LZTR1 subtype. |
| Diagnosis | Diagnosis currently relies on **NGS-based rasopathy panels**, with escalation to **WES/WGS/long-read sequencing** when needed; LZTR1 is included on many NS panels. | No subtype-specific sensitivity metric retrieved; one review compiles 51 published dominant NS cases and notes technical/interpretive challenges | Clinical review/management discussion, 2022 and 2024 (farncombe2022lztr1moleculargenetic pages 13-14, uliana2024phenotypicexpansionof pages 17-18, uliana2024phenotypicexpansionof pages 14-16) | Recommend panel-first molecular testing with segregation analysis; preserve a flag for unresolved structural/complex variant detection. |
| Overlap / differential diagnosis | There is clinically important overlap with **schwannomatosis** and occasionally NF1-like tumor phenotypes; some LZTR1 patients may warrant dual NS and schwannomatosis consideration. | Review cohort also included 123 schwannomatosis patients; reported schwannomas in dominant NS review set: n=1 | Clinical review and case-based management discussion, 2022/2024 (uliana2024phenotypicexpansionof pages 1-2, farncombe2022lztr1moleculargenetic pages 13-14, uliana2024phenotypicexpansionof pages 4-5) | Add differential-diagnosis links to schwannomatosis and note possible tumor-surveillance considerations in selected cases. |
| Prognosis / epidemiology gaps | Population prevalence, incidence, sex ratio, life expectancy, penetrance estimates, and subtype-specific longitudinal outcomes remain poorly defined for dominant LZTR1-related NS. | Available phenotype summary based on only 51 published NS patients; no robust population denominator identified | Evidence-gap synthesis from 2024 review and retrieved literature set (uliana2024phenotypicexpansionof pages 17-18, uliana2024phenotypicexpansionof pages 1-2, uliana2024phenotypicexpansionof pages 4-5) | Mark epidemiology and prognosis fields as **not well established / evidence sparse** rather than extrapolating from all-cause Noonan syndrome. |


*Table: This table summarizes the best-supported, ontology-ready facts for autosomal-dominant LZTR1-related Noonan syndrome from the retrieved evidence. It highlights the nomenclature caveat, key phenotype frequencies, mechanism, model data, diagnostic approach, and major evidence gaps.*

## 1. Disease information

Dominant LZTR1-related Noonan syndrome is a congenital, lifelong **RASopathy** characterized by variable craniofacial dysmorphism, impaired growth, congenital or developmental cardiac disease, skeletal abnormalities, hemostatic defects, ectodermal findings, and variably affected neurodevelopment. Facial features are generally most recognizable in childhood. Disease severity ranges from mild, incompletely penetrant presentations to severe multisystem disease. (uliana2024phenotypicexpansionof pages 14-16, uliana2024phenotypicexpansionof pages 1-2)

**Identifiers and synonyms**

- Preferred knowledge-base label: **Autosomal-dominant LZTR1-related Noonan syndrome**.
- OMIM disease: **#616564**, reported in the retrieved literature as **Noonan syndrome 10**.
- Broader MONDO: **MONDO:0018997, Noonan syndrome**.
- Causal gene: **LZTR1**, approved name *leucine zipper like post translational regulator 1*; Ensembl **ENSG00000099949**.
- Common terms: **LZTR1-related Noonan syndrome**, **AD LZTR1-NS**, **LZTR1-associated NS**, and **NS10**.
- ICD-10/ICD-11 and MeSH are generally assigned at the broader Noonan-syndrome level; no subtype-specific code was verified in the retrieved sources.
- “Noonan syndrome 11” should be retained only as an unverified incoming synonym, not asserted as the accepted OMIM name.

The evidence is primarily **aggregated disease-level literature**, including a 2024 synthesis of published cases, supplemented by individual case reports and DDD exome data. It is not an EHR-derived population cohort. The 2024 review assembled 51 published LZTR1-NS patients, whereas the 2019 DDD analysis screened 9,624 clinical exomes. (pagnamenta2019delineationofdominant pages 1-2, uliana2024phenotypicexpansionof pages 4-5)

## 2. Etiology, risk, and protective factors

### Causal factor

The disorder is caused by a **constitutional heterozygous pathogenic LZTR1 variant**, most characteristically a missense variant altering the Kelch-domain substrate-recognition surface. In the 2024 compilation, 77% of dominant NS variants were missense and 87% affected the Kelch domain; **p.Gly248Arg** was recurrent in six families. Dominant variants dysregulate RAS-family protein turnover and increase RAS–MAPK signaling. (uliana2024phenotypicexpansionof pages 16-17, motta2019dominantnoonansyndromecausing pages 1-2)

The 2019 DDD study found six dominantly acting substitutions—p.Arg97Leu, p.Tyr136Cys, p.Tyr136His, p.Asn145Ile, p.Ser244Cys, and p.Gly248Arg—among 9,624 exomes; five arose de novo. This clustering around KT1–KT4 supports a domain-specific dominant mechanism. (pagnamenta2019delineationofdominant pages 1-2)

### Genetic risk factors

- A de novo pathogenic variant confers disease risk to the proband and a theoretical 50% transmission risk to offspring.
- An inherited variant may produce disease with **incomplete penetrance and variable expressivity**; apparently unaffected parents therefore require careful phenotyping and segregation testing.
- Family history of Noonan features, congenital heart disease, short stature, bleeding, schwannomas, or LZTR1-related disease increases suspicion.
- Variant interpretation is difficult: more than half of 3,263 LZTR1 ClinVar submissions discussed in the 2024 review were VUS. (uliana2024phenotypicexpansionof pages 16-17, uliana2024phenotypicexpansionof pages 17-18, uliana2024phenotypicexpansionof pages 14-16)

Dominant LZTR1-NS must not be conflated with **biallelic LZTR1-NS**, in which compound-heterozygous or homozygous variants are distributed more broadly through the gene, or with schwannomatosis, which more often involves monoallelic loss-of-function variants. (pagnamenta2019delineationofdominant pages 1-2, motta2019dominantnoonansyndromecausing pages 1-2)

### Environmental, infectious, and lifestyle risk

No toxin, infection, diet, occupation, smoking behavior, or other environmental exposure is established as a cause. Maternal or paternal age effects were not quantified. Environmental factors may modify complications—nutrition and physical activity affect growth and cardiovascular health, while medications and surgery affect bleeding—but they do not replace the germline cause.

### Protective factors and gene–environment interaction

No validated protective allele, diet, exposure, or lifestyle intervention prevents the syndrome. Appropriate cardiac, developmental, growth, auditory, ophthalmologic, and hemostatic surveillance can reduce secondary morbidity but is tertiary prevention rather than biological protection. No reproducible LZTR1-specific gene–environment interaction was identified.

## 3. Phenotypes

The best subtype-specific frequency estimates come from a literature-derived cohort of **51 patients with 30 variants**: median age 17.2 years, range 2–69; 28 female, 20 male, and three with sex unreported. Short stature occurred in 68.3%, cardiac defects in 66%, skeletal abnormalities in 58%, global developmental delay in 32%, and abnormal hemostasis in 27%. Four patients had neoplasms, six café-au-lait macules, two lymphedema, and one a schwannoma. These estimates are vulnerable to referral, publication, and missing-data bias and should not be treated as population prevalence. (uliana2024phenotypicexpansionof pages 4-5)

### Ontology-ready phenotype set

- **Short stature**—growth sign, usually evident in childhood; variable persistence and severity; 68.3%. HPO: **Short stature (HP:0004322)**.
- **Cardiac defect**—congenital/developmental sign; 66% collectively. Important manifestations include **hypertrophic cardiomyopathy (HP:0001639)** and **pulmonic stenosis (HP:0001642)**. Course ranges from stable mild disease to progressive hypertrophy or hemodynamic compromise.
- **Skeletal abnormality**—physical sign; 58%. Suggested HPO concepts include **pectus excavatum**, **pectus carinatum**, scoliosis, and broad thorax; exact subtype frequencies were unavailable.
- **Global developmental delay (HP:0001263)**—neurodevelopmental sign, childhood onset; 32%; severity variable. Intellectual disability is not obligatory.
- **Abnormality of coagulation/hemostasis (HP:0001928)**—laboratory/clinical phenotype; 27%; may remain subclinical until trauma or surgery.
- **Facial dysmorphism**—congenital sign, usually more apparent in childhood: **hypertelorism (HP:0000316)**, **ptosis (HP:0000508)**, downslanting palpebral fissures, epicanthal folds, and low-set/posteriorly rotated ears. (pagnamenta2019delineationofdominant pages 1-2, uliana2024phenotypicexpansionof pages 1-2)
- **Relative macrocephaly**, webbed or short neck, and ectodermal anomalies are characteristic but lack reliable subtype frequencies.
- **Joint hypermobility (HP:0001382)** was reported in approximately half of tested NS patients in the 2024 review, but the denominator was selected and should not be generalized. (uliana2024phenotypicexpansionof pages 16-17)
- Less frequent reported findings include **lymphedema (HP:0001004)**, café-au-lait macules, renal abnormalities, hearing loss, and neoplasia. Evidence for breast cancer, ependymoma, leukemia, bladder exstrophy, mitral-valve prolapse, or Parkinson disease consists largely of isolated cases and is insufficient to define the core phenotype. (uliana2024phenotypicexpansionof pages 14-16, uliana2024phenotypicexpansionof pages 17-18)

Quality-of-life effects have not been measured with subtype-specific EQ-5D, SF-36, or PROMIS datasets. Likely burdens include exercise limitation from cardiac disease, educational support needs, reduced adult height, bleeding-related procedural risk, and repeated specialist visits. This is a clinical inference from manifestations, not a quantified LZTR1-specific result.

## 4. Genetic and molecular information

**Gene:** *LZTR1*, encoding leucine-zipper-like post-translational regulator 1, a BTB-Kelch adaptor for a CUL3 ubiquitin-ligase complex. The retrieved evidence supports a strong/definitive clinical association through human genetics and functional studies. (motta2019dominantnoonansyndromecausing pages 1-2, OpenTargets Search: Noonan syndrome-LZTR1)

**Variant classes and consequences:**

- Dominant NS: predominantly heterozygous Kelch-domain missense variants, usually **dominant negative** rather than simple haploinsufficiency.
- Recessive NS: biallelic missense, nonsense, frameshift, or splice variants; examples include p.Arg210Ter/p.Val579Met, p.Arg210Ter/p.Asp531Asn, and c.1149+1G>T/p.Arg688Cys.
- Schwannomatosis: more frequently heterozygous inactivating/frameshift variants, with tumor formation generally requiring additional somatic events.
- A frameshift such as c.1602del, p.Lys534Asnfs*22 illustrates interpretive overlap: variant class alone does not establish whether the clinical outcome is NS or schwannomatosis. (pagnamenta2019delineationofdominant pages 1-2, uliana2024phenotypicexpansionof pages 16-17, uliana2024phenotypicexpansionof pages 14-16)

Dominant variants preserve much of LZTR1 stability, localization, and CUL3 binding but compromise substrate recognition. No validated population allele-frequency threshold specific to this subtype was retrieved; credible dominant pathogenic variants should generally be very rare or absent from population databases and evaluated using ancestry-aware gnomAD frequencies, segregation, de novo status, domain location, computational/structural evidence, and functional data.

No established modifier gene, protective allele, recurrent chromosomal abnormality, or diagnostic disease-specific methylation signature was found. Composite phenotypes can occur: one DDD patient also carried biallelic *NEB* loss-of-function variants. (pagnamenta2019delineationofdominant pages 1-2)

## 5. Environmental information

Environmental toxins, radiation, pollution, occupational exposures, lifestyle behaviors, and infectious agents are **not etiologic**. Routine vaccination follows standard schedules unless contraindicated by an individual complication. Smoking avoidance, heart-healthy nutrition, safe exercise prescribed around cardiac disease, and avoidance of medications that worsen bleeding are sensible supportive measures but are not LZTR1-specific disease modifiers.

## 6. Mechanism and pathophysiology

### Upstream causal chain

**Germline Kelch-domain LZTR1 variant → defective dominant-negative substrate recognition by CUL3–LZTR1 → reduced interaction/ubiquitination and altered degradation or localization of RAS-family substrates, particularly RIT1, MRAS, and KRAS → enlarged cellular RAS protein pool → increased MEK/ERK pathway output → altered developmental growth, cardiomyocyte growth, craniofacial morphogenesis, lymphatic/vascular biology, and neurodevelopment → Noonan phenotype.** (motta2019dominantnoonansyndromecausing pages 1-2, abe2024dysregulationofras pages 8-11, abe2024dysregulationofras pages 1-2)

The key 2019 functional paper concluded that dominant variants, unlike recessive missense changes tested, enhance stimulus-dependent RAS–MAPK signaling. An exact abstract statement is: **“dominant NS-causing mutations do not perturb binding of LZTR1 to CUL3 … but are predicted to affect the surface of the Kelch domain mediating substrate binding.”** Published in *Human Molecular Genetics*, online November 2018/volume 2019; DOI: https://doi.org/10.1093/hmg/ddy412; PMID 30481304. (motta2019dominantnoonansyndromecausing pages 1-2, motta2019dominantnoonansyndromecausing pages 1-1)

### Cellular, tissue, and multi-omics evidence

In 2024, two knock-in lines—**Lztr1G245R/+** and **Lztr1R409C/+**, corresponding to human p.Gly248Arg and p.Arg412Cys—were generated. Male mutants had low birth weight, distinctive facial morphology, enlarged cardiomyocytes, and cardiac hypertrophy. Left ventricles showed increased MRAS and RIT1, while RNA sequencing and DIA proteomics indicated MAPK-pathway activation. Mutant mouse embryonic fibroblasts showed increased KRAS/MRAS/RIT1 and phospho-MEK/ERK. Haploinsufficient Lztr1+/− mice lacked the same phenotype, supporting dominant negativity rather than dosage loss alone. (abe2024dysregulationofras pages 8-11, abe2024dysregulationofras pages 1-2)

An exact 2024 abstract statement is: **“Treatment with the MEK inhibitor trametinib ameliorated cardiac hypertrophy in mutant male mice.”** This provides strong preclinical target validation, not evidence of human efficacy. *JCI Insight*, published November 2024; DOI: https://doi.org/10.1172/jci.insight.182382. (abe2024dysregulationofras pages 1-2)

The R409C/+ model also exhibited smaller rounder skulls, blunt snouts, hypertelorism, splenomegaly, renal enlargement, embryonic edema, hemorrhage, lymphatic abnormalities, and reduced long-term survival; only about 25% reportedly survived to two years, with sudden deaths after one year. Homozygotes were embryonically lethal. These findings should not be directly converted to human prognosis. (abe2024dysregulationofras pages 2-4)

Suggested GO biological-process annotations include **RAS protein signal transduction**, **MAPK cascade**, **protein ubiquitination**, **proteasome-mediated protein catabolic process**, **regulation of cell growth**, **heart development**, and **lymph vessel development**. Relevant cellular components include the **CUL3 ubiquitin-ligase complex**, cytoplasm, Golgi/endosomal compartments, and plasma-membrane-associated signaling complexes. Suggested CL concepts include **cardiomyocyte**, **endothelial cell**, **vascular endothelial cell**, **lymphatic endothelial cell**, **fibroblast**, and neural-crest-derived craniofacial mesenchymal cells.

No validated human LZTR1-NS metabolomic, lipidomic, spatial-transcriptomic, or single-cell atlas was identified. The 2024 cardiac RNA-seq/proteomics study is the most important recent multi-omics advance.

## 7. Anatomical structures affected

Primary systems are:

- **Cardiovascular:** heart, myocardium, pulmonary valve, septa, and vasculature. Suggested UBERON concepts: heart, cardiac ventricle, left ventricle, myocardium, pulmonary valve, and blood vessel.
- **Lymphatic:** lymphatic vessels and potentially pleural/pulmonary lymphatics; edema and lymphedema may occur.
- **Craniofacial:** skull, facial skeleton, eyelids, external ears, and neck.
- **Musculoskeletal:** thoracic cage, spine, joints, and connective tissue.
- **Nervous system:** brain and peripheral nerves indirectly through neurodevelopment; Schwann-cell tumors are an overlap concern, not a universal NS manifestation.
- **Hematologic/vascular:** coagulation system, platelets, and endothelial barrier.
- **Renal/genitourinary, auditory, ocular, and ectodermal structures** may be involved secondarily.

No consistent lateralization is known. Cardiac hypertrophy and craniofacial changes are generally bilateral/systemic rather than unilateral.

## 8. Temporal development

The initiating variant is present from conception. Craniofacial, cardiac, lymphatic, and skeletal abnormalities may be prenatal or congenital; feeding, growth, developmental, hearing, bleeding, and learning problems typically become evident during infancy or childhood. Facial gestalt evolves and may become less conspicuous in adulthood. Adult-onset schwannomas and other possible neoplasms broaden the surveillance horizon, although their incidence in LZTR1-NS is unknown. (uliana2024phenotypicexpansionof pages 17-18, uliana2024phenotypicexpansionof pages 1-2)

The course is **chronic and lifelong**, not relapsing-remitting. Individual manifestations differ: congenital pulmonary stenosis may remain stable or require intervention; hypertrophic cardiomyopathy can progress; short stature evolves through childhood; developmental disability is generally nonregressive; and bleeding may be episodic around trauma or procedures. There are no formal disease stages or remission criteria. Prenatal/infant cardiac and lymphatic disease and childhood developmental periods are important intervention windows.

## 9. Inheritance and population

Inheritance is **autosomal dominant**, frequently de novo, with incomplete penetrance and variable expressivity. Five of six dominant variants found in the DDD analysis were de novo. Familial transmission is documented, and intrafamilial variability can be substantial. Anticipation is not established. Parental germline mosaicism is biologically possible for an apparently de novo variant but has not been quantified. Consanguinity is relevant mainly to recessive LZTR1-NS, not the dominant target disorder. (pagnamenta2019delineationofdominant pages 1-2, uliana2024phenotypicexpansionof pages 16-17)

Subtype-specific prevalence, incidence, carrier frequency, founder effects, ethnic enrichment, geographic variation, and sex ratio remain unknown. LZTR1 variants explained approximately **0.1% of all 9,624 DDD exomes**, but that is not a prevalence estimate and includes a heterogeneous developmental-disorder referral population. The 2024 published-case cohort showed no significant sex-dependent phenotype difference. (pagnamenta2019delineationofdominant pages 1-2, uliana2024phenotypicexpansionof pages 16-17)

## 10. Diagnostics

### Clinical assessment

A clinical diagnosis should be considered with the combination of characteristic facial appearance, short stature, pulmonary stenosis or hypertrophic cardiomyopathy, pectus deformity, developmental differences, cryptorchidism, lymphatic disease, or bleeding. There is no validated clinical scoring system specific to LZTR1.

Baseline evaluation should include:

1. Echocardiography and ECG, with cardiology follow-up determined by lesion and age.
2. Growth, nutrition, pubertal, and endocrine assessment.
3. Developmental, behavioral, educational, speech, and motor assessment.
4. CBC, PT/INR, aPTT, and specialist-directed coagulation/platelet studies, especially before surgery.
5. Hearing and ophthalmologic assessment.
6. Renal ultrasound and examination for thoracic/spinal or lymphatic abnormalities where indicated.
7. Detailed skin and neurologic examination, with inquiry about focal pain, weakness, or masses.

### Molecular testing algorithm

1. Use a comprehensive **RASopathy/Noonan multigene NGS panel** containing *LZTR1*, *PTPN11*, *SOS1*, *RAF1*, *RIT1*, *KRAS*, *NRAS*, *MRAS*, *SOS2*, *SHOC2*, *PPP1CB*, *CBL*, and other validated genes, with copy-number analysis.
2. Confirm the variant and test both parents. Segregation is essential because de novo evidence supports ACMG PS2/PM6 and phase/allelic evidence helps distinguish dominant from recessive disease.
3. If panel testing is negative, use trio WES or WGS. WGS and long-read sequencing may resolve structural, intronic, or technically difficult variants.
4. CMA is appropriate when there are atypical features or suspicion of a copy-number disorder but is not the primary test for a Kelch-domain sequence variant.
5. Karyotype/FISH, mitochondrial sequencing, and repeat-expansion testing are not routine unless another diagnosis is suspected. (farncombe2022lztr1moleculargenetic pages 13-14, uliana2024phenotypicexpansionof pages 17-18)

RNA analysis can clarify a suspected splice variant; functional MAPK or ubiquitination assays remain research tools. No validated circulating biomarker, liquid biopsy, proteomic, metabolomic, or methylation diagnostic is available.

### Differential diagnosis

Differentials include other molecular forms of Noonan syndrome, Noonan syndrome with multiple lentigines, cardiofaciocutaneous syndrome, Costello syndrome, NF1/Neurofibromatosis-Noonan phenotype, Noonan-like syndrome with loose anagen hair, Turner syndrome, 22q11.2 deletion syndrome, and isolated congenital heart disease. LZTR1 schwannomatosis is particularly important when schwannomas, chronic focal pain, or nerve tumors occur.

The 2022 overlap review proposed baseline brain/spine MRI in late childhood or early adulthood and longitudinal neurology/NF-specialist care for selected LZTR1 patients. This is an expert proposal based on overlap and limited cases, not universally adopted evidence-based screening. (farncombe2022lztr1moleculargenetic pages 13-14)

## 11. Outcome and prognosis

No LZTR1-subtype-specific five- or ten-year survival rate, life expectancy, mortality rate, disability weight, or validated prognostic model exists. Most morbidity is expected to reflect the severity of cardiac disease, lymphatic complications, neurodevelopmental disability, feeding/growth problems, and bleeding. Human evidence is insufficient to infer the reduced survival observed in one mouse line. (abe2024dysregulationofras pages 2-4)

Potential adverse prognostic features include severe neonatal lymphatic disease, progressive hypertrophic cardiomyopathy, significant pulmonary stenosis, major bleeding diathesis, and severe developmental impairment. Early diagnosis and multidisciplinary management improve the opportunity to treat complications, but they do not remove the germline disorder.

Cancer risk is uncertain at the subtype level. The 2024 dominant LZTR1 compilation recorded four neoplasms among 51 published patients, but publication bias and heterogeneous follow-up prevent calculation of penetrance. The approximately 4% cancer risk by age 20 cited for broader NS should not be assigned specifically to dominant LZTR1-NS. (uliana2024phenotypicexpansionof pages 16-17, uliana2024phenotypicexpansionof pages 4-5)

## 12. Treatment and current applications

There is no approved etiologic therapy for dominant LZTR1-NS. Current care is phenotype-directed and multidisciplinary.

- **Cardiac:** standard medical, catheter, or surgical management of pulmonary stenosis, septal defects, and hypertrophic cardiomyopathy. NCIT concepts: cardiac surgery, balloon valvuloplasty, beta-blocker therapy.
- **Growth:** optimize nutrition and treat endocrine abnormalities. Recombinant human growth hormone/somatropin is used in broader Noonan syndrome, but decisions should account for cardiac status, tumor history, and uncertain LZTR1/schwannomatosis overlap. Evidence is not LZTR1-specific.
- **Development:** early intervention, physical therapy, occupational therapy, speech-language therapy, individualized education, and neuropsychological support.
- **Bleeding:** identify factor, von Willebrand, or platelet defects; use hematology-directed perioperative planning. Avoid empiric aspirin/NSAID use where bleeding risk is unresolved.
- **Lymphatic disease:** nutrition modification, drainage/procedural management, and specialist treatment according to anatomy and severity.
- **Hearing/vision/orthopedic/feeding:** standard corrective and rehabilitative care.
- **Schwannoma concern:** symptom-directed MRI and referral to neurologic, neuro-oncology, or NF specialists; surgery or pain management as appropriate. (farncombe2022lztr1moleculargenetic pages 13-14)

### Targeted and experimental therapy

MEK inhibition has the strongest mechanism-based rationale. In the 2024 dominant LZTR1 mouse model, **trametinib** improved cardiac hypertrophy, whereas rapamycin did not, supporting MEK/ERK rather than mTOR as the proximal therapeutic target in that model. This remains preclinical for the LZTR1 subtype. (abe2024dysregulationofras pages 8-11, abe2024dysregulationofras pages 1-2)

Broader Noonan trials identified by ClinicalTrials.gov included growth-hormone studies, simvastatin, and MEK-inhibitor protocols. Of particular relevance, **NCT06555237**, a phase 2 study of MEK inhibitors for RASopathy-associated hypertrophic cardiomyopathy, was recruiting 40 participants; **NCT01556568**, a phase 2 MEK162 study, was withdrawn with zero enrollment. These are not LZTR1-specific efficacy data. Other broader-NS studies included NCT00452725, NCT01529840, NCT01927861, NCT02713945, NCT05723835, and NCT06668805. No human interventional trial restricted to dominant LZTR1-NS was identified.

Suggested NCIT intervention concepts include **Trametinib**, **MEK inhibitor**, **Somatropin**, physical therapy, occupational therapy, speech therapy, genetic counseling, echocardiography, and cardiac surgical procedure. Gene replacement, CRISPR editing, ASO/siRNA therapy, and cell therapy are not established clinical options.

## 13. Prevention

Primary prevention by lifestyle or vaccination is impossible because the disorder is germline. Reproductive options include preconception counseling, parental testing, prenatal diagnosis after chorionic-villus sampling or amniocentesis, and preimplantation genetic testing for a known familial variant. A clinically affected heterozygous individual generally has a 50% transmission risk per pregnancy, modified by uncertainty from incomplete penetrance and variable expressivity.

Secondary and tertiary prevention consists of cascade testing, early cardiac and developmental assessment, preoperative hemostasis evaluation, hearing/vision screening, growth monitoring, and prompt investigation of neurologic symptoms or masses. Population newborn screening and general-population carrier screening are not established. No infectious prophylaxis, vaccine, dietary supplement, or preventive drug specifically prevents LZTR1-NS.

## 14. Other species and natural disease

No naturally occurring veterinary syndrome definitively equivalent to human dominant LZTR1-NS was identified. The mechanism is evolutionarily conserved sufficiently for human variants to produce Noonan-like disease in mice. Zoonotic transmission and cross-species contagion are not applicable.

Relevant taxa include **Homo sapiens (NCBI Taxon 9606)** and experimental **Mus musculus (NCBI Taxon 10090)**. Orthologous *Lztr1* should be linked through NCBI Gene/Alliance records. No breed-specific VBO annotation is supported.

## 15. Model organisms and experimental systems

The most disease-specific model is the 2024 mammalian knock-in system:

- **Lztr1G245R/+** and **Lztr1R409C/+** mice reproduce human dominant variants p.Gly248Arg and p.Arg412Cys.
- Recapitulated features include low birth weight, craniofacial anomalies, cardiomyocyte enlargement, cardiac hypertrophy, edema/lymphatic defects, hemorrhage, and organ enlargement; severity was stronger in males in the reported experiments.
- Left-ventricular RNA-seq and proteomics showed MAPK activation and increased RIT1/MRAS; trametinib produced pharmacologic rescue.
- Homozygous mutants were embryonically lethal, while simple haploinsufficiency did not reproduce the dominant phenotype. (abe2024dysregulationofras pages 8-11, abe2024dysregulationofras pages 1-2, abe2024dysregulationofras pages 2-4)

Mouse embryonic fibroblasts provide an in-vitro system for RAS abundance, phospho-MEK/ERK, protein-interaction, ubiquitination, and drug-response assays. Human iPSC-derived cardiomyocytes have been used chiefly for biallelic LZTR1 disease and should not be assumed to model the dominant subtype identically.

Model limitations include species-specific development, sex effects not yet validated in humans, variant-specific phenotypes, supraphysiologic drug exposure concerns, and inability to capture the full human cognitive and tumor spectrum. Useful resources include MGI, IMPC, IMSR/MMRRC, and Cellosaurus for model registration.

## Recent developments and expert interpretation

The major 2024 clinical advance was the synthesis of **51 dominant LZTR1-NS cases**, yielding the first relatively stable subtype-level frequency estimates and highlighting adult phenotypic variability. Its abstract states: **“This review confirms that autosomal dominant LZTR1-related disorders exhibit an extreme phenotypic variability, ranging from relatively mild manifestations to severe and multi-systemic involvement.”** *Genes*, published July 2024; DOI: https://doi.org/10.3390/genes15070916. (uliana2024phenotypicexpansionof pages 1-2)

The major 2024 mechanistic advance was direct in-vivo demonstration that human-equivalent dominant variants disturb RAS proteostasis, activate cardiac MAPK signaling, and generate trametinib-responsive hypertrophy. Together, these data favor a **variant- and mechanism-specific dominant-negative model**, rather than treating all LZTR1 pathogenic variants as interchangeable loss-of-function alleles. (abe2024dysregulationofras pages 8-11, abe2024dysregulationofras pages 1-2)

Expert analysis should remain conservative in three areas: (1) do not equate the user label “NS11” with an established identifier without database confirmation; (2) do not extrapolate schwannomatosis risk equally to every Kelch-domain NS variant; and (3) do not treat preclinical trametinib rescue as established human therapy. Larger longitudinal, genotype-stratified cohorts—including adults and systematically assessed relatives—are needed to estimate penetrance, tumor risk, survival, quality of life, and treatment response. (uliana2024phenotypicexpansionof pages 17-18)

## Evidence gaps for knowledge-base encoding

Subtype-specific incidence, prevalence, penetrance, life expectancy, sex ratio, ethnic distribution, founder variants, carrier frequency, standardized quality-of-life scores, metabolomics, lipidomics, single-cell/spatial data, validated biomarkers, and human treatment-response rates are **not available** from the retrieved evidence. These fields should be encoded as “unknown/not established,” rather than populated using statistics for all Noonan syndromes.

References

1. (uliana2024phenotypicexpansionof pages 14-16): Vera Uliana, Enrico Ambrosini, Antonietta Taiani, Sofia Cesarini, Ilenia Rita Cannizzaro, Anna Negrotti, Walter Serra, Gabriele Quintavalle, Lucia Micale, Carmela Fusco, Marco Castori, Davide Martorana, Beatrice Bortesi, Laura Belli, Antonio Percesepe, Francesco Pisani, and Valeria Barili. Phenotypic expansion of autosomal dominant lztr1-related disorders with special emphasis on adult-onset features. Jul 2024. URL: https://doi.org/10.3390/genes15070916, doi:10.3390/genes15070916. This article has 7 citations.

2. (uliana2024phenotypicexpansionof pages 1-2): Vera Uliana, Enrico Ambrosini, Antonietta Taiani, Sofia Cesarini, Ilenia Rita Cannizzaro, Anna Negrotti, Walter Serra, Gabriele Quintavalle, Lucia Micale, Carmela Fusco, Marco Castori, Davide Martorana, Beatrice Bortesi, Laura Belli, Antonio Percesepe, Francesco Pisani, and Valeria Barili. Phenotypic expansion of autosomal dominant lztr1-related disorders with special emphasis on adult-onset features. Jul 2024. URL: https://doi.org/10.3390/genes15070916, doi:10.3390/genes15070916. This article has 7 citations.

3. (OpenTargets Search: Noonan syndrome-LZTR1): Open Targets Query (Noonan syndrome-LZTR1, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

4. (uliana2024phenotypicexpansionof pages 4-5): Vera Uliana, Enrico Ambrosini, Antonietta Taiani, Sofia Cesarini, Ilenia Rita Cannizzaro, Anna Negrotti, Walter Serra, Gabriele Quintavalle, Lucia Micale, Carmela Fusco, Marco Castori, Davide Martorana, Beatrice Bortesi, Laura Belli, Antonio Percesepe, Francesco Pisani, and Valeria Barili. Phenotypic expansion of autosomal dominant lztr1-related disorders with special emphasis on adult-onset features. Jul 2024. URL: https://doi.org/10.3390/genes15070916, doi:10.3390/genes15070916. This article has 7 citations.

5. (uliana2024phenotypicexpansionof pages 16-17): Vera Uliana, Enrico Ambrosini, Antonietta Taiani, Sofia Cesarini, Ilenia Rita Cannizzaro, Anna Negrotti, Walter Serra, Gabriele Quintavalle, Lucia Micale, Carmela Fusco, Marco Castori, Davide Martorana, Beatrice Bortesi, Laura Belli, Antonio Percesepe, Francesco Pisani, and Valeria Barili. Phenotypic expansion of autosomal dominant lztr1-related disorders with special emphasis on adult-onset features. Jul 2024. URL: https://doi.org/10.3390/genes15070916, doi:10.3390/genes15070916. This article has 7 citations.

6. (pagnamenta2019delineationofdominant pages 1-2): Alistair T. Pagnamenta, Pamela J. Kaisaki, Fenella Bennett, Emma Burkitt‐Wright, Hilary C. Martin, Matteo P. Ferla, John M. Taylor, Lianne Gompertz, Nayana Lahiri, Katrina Tatton‐Brown, Ruth Newbury‐Ecob, Alex Henderson, Shelagh Joss, Astrid Weber, Jenny Carmichael, Peter D. Turnpenny, Shane McKee, Francesca Forzano, Tazeen Ashraf, Kimberley Bradbury, Deborah Shears, Usha Kini, Anna de Burca, Edward Blair, Jenny C. Taylor, and Helen Stewart. Delineation of dominant and recessive forms of lztr1‐associated noonan syndrome. Clinical Genetics, 95:693-703, Apr 2019. URL: https://doi.org/10.1111/cge.13533, doi:10.1111/cge.13533. This article has 71 citations and is from a peer-reviewed journal.

7. (motta2019dominantnoonansyndromecausing pages 1-2): Marialetizia Motta, Miray Fidan, Emanuele Bellacchio, Francesca Pantaleoni, Konstantin Schneider-Heieck, Simona Coppola, Guntram Borck, Leonardo Salviati, Martin Zenker, Ion C Cirstea, and Marco Tartaglia. Dominant noonan syndrome-causing lztr1 mutations specifically affect the kelch domain substrate-recognition surface and enhance ras-mapk signaling. Human Molecular Genetics, 28:1007–1022, Nov 2019. URL: https://doi.org/10.1093/hmg/ddy412, doi:10.1093/hmg/ddy412. This article has 120 citations and is from a domain leading peer-reviewed journal.

8. (motta2019dominantnoonansyndromecausing pages 1-1): Marialetizia Motta, Miray Fidan, Emanuele Bellacchio, Francesca Pantaleoni, Konstantin Schneider-Heieck, Simona Coppola, Guntram Borck, Leonardo Salviati, Martin Zenker, Ion C Cirstea, and Marco Tartaglia. Dominant noonan syndrome-causing lztr1 mutations specifically affect the kelch domain substrate-recognition surface and enhance ras-mapk signaling. Human Molecular Genetics, 28:1007–1022, Nov 2019. URL: https://doi.org/10.1093/hmg/ddy412, doi:10.1093/hmg/ddy412. This article has 120 citations and is from a domain leading peer-reviewed journal.

9. (abe2024dysregulationofras pages 8-11): Taiki Abe, Kaho Morisaki, Tetsuya Niihori, Miho Terao, Shuji Takada, and Yoko Aoki. Dysregulation of ras proteostasis by autosomal-dominant lztr1 mutation induces noonan syndrome–like phenotypes in mice. JCI Insight, Nov 2024. URL: https://doi.org/10.1172/jci.insight.182382, doi:10.1172/jci.insight.182382. This article has 11 citations and is from a domain leading peer-reviewed journal.

10. (abe2024dysregulationofras pages 1-2): Taiki Abe, Kaho Morisaki, Tetsuya Niihori, Miho Terao, Shuji Takada, and Yoko Aoki. Dysregulation of ras proteostasis by autosomal-dominant lztr1 mutation induces noonan syndrome–like phenotypes in mice. JCI Insight, Nov 2024. URL: https://doi.org/10.1172/jci.insight.182382, doi:10.1172/jci.insight.182382. This article has 11 citations and is from a domain leading peer-reviewed journal.

11. (abe2024dysregulationofras pages 2-4): Taiki Abe, Kaho Morisaki, Tetsuya Niihori, Miho Terao, Shuji Takada, and Yoko Aoki. Dysregulation of ras proteostasis by autosomal-dominant lztr1 mutation induces noonan syndrome–like phenotypes in mice. JCI Insight, Nov 2024. URL: https://doi.org/10.1172/jci.insight.182382, doi:10.1172/jci.insight.182382. This article has 11 citations and is from a domain leading peer-reviewed journal.

12. (farncombe2022lztr1moleculargenetic pages 13-14): Kirsten M. Farncombe, Emily Thain, Carolina Barnett-Tapia, Hamid Sadeghian, and Raymond H. Kim. Lztr1 molecular genetic overlap with clinical implications for noonan syndrome and schwannomatosis. BMC Medical Genomics, Jul 2022. URL: https://doi.org/10.1186/s12920-022-01304-x, doi:10.1186/s12920-022-01304-x. This article has 25 citations and is from a peer-reviewed journal.

13. (uliana2024phenotypicexpansionof pages 17-18): Vera Uliana, Enrico Ambrosini, Antonietta Taiani, Sofia Cesarini, Ilenia Rita Cannizzaro, Anna Negrotti, Walter Serra, Gabriele Quintavalle, Lucia Micale, Carmela Fusco, Marco Castori, Davide Martorana, Beatrice Bortesi, Laura Belli, Antonio Percesepe, Francesco Pisani, and Valeria Barili. Phenotypic expansion of autosomal dominant lztr1-related disorders with special emphasis on adult-onset features. Jul 2024. URL: https://doi.org/10.3390/genes15070916, doi:10.3390/genes15070916. This article has 7 citations.

## Artifacts

- [Edison artifact artifact-00](Noonan_Syndrome_11-deep-research-falcon_artifacts/artifact-00.md)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 6 |
| Resolved | 6 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 6 |
| On topic | 5 |
| Off topic | 0 |

All extracted references resolved successfully.